|
Real-time Estimate
Cboe BZX
11:46:57 2026-09-23 EDT
|
5-day change | 1st Jan Change | ||
| 45.70 USD | -1.02% |
|
-2.29% | +13.21% |
| 09-04 | CONMED Corporation Announces Voluntary Recall of Genesys Crossft Suture Anchor | CI |
| 07-30 | CONMED Q2 Adjusted Earnings, Revenue Rise; 2026 Guidance Raised | MT |
Business description: CONMED Corporation
Number of employees: 3,900
Sales by Activity: CONMED Corporation
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Development, Manufacturing and Sale of Surgical Devices and Related Equipment | 1.01B | 1.05B | 1.24B | 1.31B | 1.37B |
Geographical breakdown of sales: CONMED Corporation
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 553M | 579M | 700M | 748M | 775M |
Europe, Middle East & Africa | 190M | 198M | 226M | 243M | 265M |
Asia Pacific | 171M | 162M | 197M | 195M | 209M |
Americas (Excluding The United States) | 97.19M | 106M | 121M | 121M | 127M |
Executive Committee: CONMED Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
Patrick Beyer
CEO | Chief Executive Officer | 60 | 2024-12-31 |
John Gallagher
DFI | Director of Finance/CFO | 53 | 2026-07-14 |
Brent Lalomia
CTO | Chief Tech/Sci/R&D Officer | 50 | 2024-12-31 |
Dalton Henry
IRC | Investor Relations Contact | - | - |
Hollie Foust
LAW | General Counsel | 51 | 2024-11-01 |
Composition of the Board of Directors: CONMED Corporation
| Director | Title | Age | Since |
|---|---|---|---|
Charles Farkas
BRD | Director/Board Member | 74 | 2014-07-22 |
Patrick Beyer
BRD | Director/Board Member | 60 | 2024-12-31 |
David Bronson
BRD | Director/Board Member | 72 | 2015-06-30 |
| Director/Board Member | 60 | 2019-09-21 | |
LaVerne Council
CHM | Chairman | 64 | 2025-05-20 |
Mark Kaye
BRD | Director/Board Member | 47 | 2025-02-23 |
Kim Kelderman
BRD | Director/Board Member | 59 | 2025-09-07 |
Celine Martin
BRD | Director/Board Member | 52 | 2026-06-30 |
Jeffrey Mirviss
BRD | Director/Board Member | 60 | 2026-06-30 |
Company details: CONMED Corporation
Group companies: CONMED Corporation
| Name | Category and Sector |
|---|---|
Linvatec Belgium NV | |
Linvatec Nederland BV
 Linvatec Nederland BV Medical SpecialtiesHealth Technology Manufactures and distributes medical products |
Medical Specialties
|
Linvatec Canada ULC | |
Linvatec Europe SRL | |
CONMED Linvatec Australia Pty Ltd. |
Other Medical Equipment, Supplies & Distribution
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.02% | -2.29% | -5.32% | -54.93% | 1.38B | |
| +0.10% | +1.66% | -23.42% | +6.76% | 179B | |
| -0.72% | -2.33% | -4.75% | +13.10% | 116B | |
| +0.56% | -0.63% | +4.66% | +69.05% | 60B | |
| +0.12% | +0.83% | -1.69% | -31.27% | 49.85B | |
| -0.22% | +1.23% | +7.80% | +45.79% | 48.05B | |
| -1.28% | +1.81% | +30.38% | +3.32% | 33.79B | |
| -0.49% | +4.18% | - | - | 30.21B | |
| +0.18% | +2.65% | +48.17% | -1.06% | 26.12B | |
| -0.39% | +6.03% | +9.83% | -9.35% | 22.98B | |
| Average | -0.26% | +1.34% | +7.29% | +4.60% | 56.79B | |
| Weighted average by Cap. | -0.10% | +0.43% | -3.13% | +13.60% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CNMD Stock
- Company CONMED Corporation
Select your edition
All financial news and data tailored to specific country editions
